Renalytix Q2 EPS $(0.09), Inline, Sales $709.00K Miss $750.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Renalytix (NASDAQ:RNLX) reported Q2 EPS of $(0.09), meeting analyst estimates but reported sales of $709K, missing the $750K estimate. This represents a 35.71% improvement in EPS and a 40.52% decrease in sales year-over-year.
February 15, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Renalytix reported a Q2 EPS of $(0.09), in line with estimates, but missed sales forecasts with $709K versus the expected $750K. Year-over-year, EPS improved by 35.71%, while sales decreased by 40.52%.
The mixed earnings report, with EPS meeting expectations but sales missing estimates, could lead to short-term negative sentiment among investors. The significant year-over-year decrease in sales might raise concerns about the company's growth trajectory, potentially impacting the stock price negatively in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100